Print this page    •   Back to Web version of article

The Body Covers: The 36th Annual Meeting of the Infectious Diseases Society of America

Abstract 5: Cervicovaginal and Plasma HIV-1 Viral Load Among HIV-infected Women on HAART and Non-HAART Therapy

Coverage provided by Frederick L. Altice, M.D.

November 13, 1998

This was a cross-sectional study of 176 HIV-infected women (46% were IDUs) who had paired viral load assays (using NASBA) from the cervix (CVL) and plasma (PVL). Immunologically, 24% had a CD4 count < 200 cells/mL, 51% had a CD4 count 200-500 cells/mL, and 25% had a CD4 count > 500 cells/mL. Regarding antiretroviral therapy, 29% were on no treatment, 35% were on non-HAART antiretroviral therapy, and 36% were on HAART. The lower limit of detection for the NASBA assay was 400 copies/mL. The proportion of women whose PVL was detectable was 69% (mean = 22,000 copies/mL) and was significantly lower than found in the cervical (CVL) secretions (23%, mean = 5,000 copies/mL). Of the 122 women whose PVL was detectable, 39 (32%) also had detectable CVL. Conversely, for the 54 women whose PVL was non-detectable, 98% had a non-detectable CVL. For those with a detectable PVL, the magnitude of the PVL was strongly correlated with a detectable CVL (for those with a PVL 400-10,000 copies/mL, 8% had a detectable CVL; for those with a PVL > 10,000 copies/mL, 47% had a detectable CVL). In the multiple logistic regression analysis, having a PVL > 10,000 copies/mL (OR=30.3), and being on no antiretroviral therapy were independently correlated with predicting those with a detectable CVL; having a CD4 <200 almost achieved statistical significance. Age, race and route of transmission were not associated with a detectable CVL.

This study, similar to others, indicate that about 50% of individuals on HAART in community-derived samples have non-detectable viral loads, however the levels in the cervix may be incredibly lower with 89% of those on HAART having non-detectable CVLs. It also supports other clinical findings of a reduction in PVL is associated with a reduction in CVL. The implications for the use of HAART in reducing HIV-1 sexual transmission remain undetermined.




This article was provided by TheBodyPRO.com. Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:
http://www.thebody.com/content/art15396.html

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.